Buprenorphine and methadone are evidence-based treatments that reduce illicit opioid use and mortality; extended-release naltrexone may suit selected patients after an opioid-free period. Availability and rules vary by country.
AddictionInfo Editorial Team 8 minute read Evidence checked September 4, 2026
Clinical overview
Quick answer
Buprenorphine and methadone are evidence-based treatments that reduce illicit opioid use and mortality; extended-release naltrexone may suit selected patients after an opioid-free period. Availability and rules vary by country.
Evidence checked4 September 2026
Editorial standardReviewed against current clinical and public-health guidance
ScopeEducation only—not diagnosis or individual medical advice
What this means
Medication choice should be shared, individualised, and supported by monitoring. Arbitrary time limits or forced tapering can destabilise recovery.
Key distinctions
Induction timing matters
interactions and sedation require review
psychosocial support should be offered without making it an unnecessary barrier to medication.
Signs and patterns clinicians assess
A clinician looks at the pattern over time, its severity, the person’s baseline, and the consequences—not at one isolated behaviour. Relevant features can include:
craving, loss of control, or use outside the prescribed plan
sedation, pinpoint pupils, slowed breathing, constipation, or repeated intoxication
continued use despite overdose, health, relationship, financial, or legal harms
withdrawal symptoms such as aches, sweating, diarrhoea, nausea, anxiety, and insomnia
return to use after detox or abstinence, when reduced tolerance can sharply increase overdose risk
These signs are not a self-diagnosis. Intoxication, withdrawal, prescribed use, pain, sleep disorders, and mental-health conditions can overlap, so assessment should establish what is happening and what is immediately unsafe.
Health and safety risks
Risk depends on the substance or medicine, route, dose, frequency, combinations, physical health, mental health, and environment. Important concerns include:
fatal respiratory depression and overdose
unpredictable potency, especially with illicit fentanyl and mixed drug supplies
infection and vascular injury when drugs are injected
dangerous sedation when combined with alcohol, benzodiazepines, gabapentinoids, or other depressants
loss of tolerance after detoxification, incarceration, hospitalisation, or residential treatment
Assessment and treatment
Good care starts with consent, dignity, and a clear assessment of immediate risk. Treatment intensity should be matched to clinical need rather than to marketing labels or a fixed programme length.
rapid access to an opioid-use assessment and overdose-prevention plan
naloxone access and training for the person and people around them
evidence-based medication such as buprenorphine or methadone where available and appropriate
management of pain, mental health, infection risk, housing, and social needs
continuing care rather than detoxification as a stand-alone intervention
Recovery plans should state who is responsible for medication, crisis support, physical-health follow-up, family communication, and continuing care. A lapse should trigger prompt reassessment and additional support—not abandonment or shame.
When to seek urgent help
Suspect opioid overdose when a person is unresponsive, breathing slowly or not at all, making choking or gurgling sounds, or has blue/grey lips or fingertips. Call emergency services, give naloxone if available, provide rescue breathing or CPR as trained, and stay until help arrives.
Questions to ask a treatment provider
Who performs the medical and psychiatric assessment, and what are their current qualifications and registrations?
How is withdrawal, overdose, suicide risk, medication, and physical illness managed?
Which treatments are offered for this specific condition, and what evidence supports them?
What happens if symptoms worsen or hospital care is required?
How are outcomes, complaints, safeguarding, discharge, and continuing care handled?
Medication is a core treatment for opioid use disorder
Medication for opioid use disorder can reduce withdrawal, craving, illicit opioid use and overdose risk. The main options are methadone, buprenorphine and extended-release or oral naltrexone. They work differently and have different initiation requirements, but all should be considered within an individual clinical assessment.
Medication is not simply a short detox tool. Many people benefit from continuing treatment for months or years. Duration should reflect benefit, risk and preference rather than pressure to become medication-free on a fixed timetable.
Methadone
Methadone is a long-acting opioid agonist that prevents withdrawal and reduces craving when taken at a stable therapeutic dose. It is provided through regulated systems that vary by country. Dose and monitoring are individualised because methadone can accumulate and interact with other medicines.
Alcohol, benzodiazepines and other sedatives can increase respiratory depression. This risk requires careful management, not automatic denial of treatment. Prescribers should know every substance and medicine being used.
Buprenorphine
Buprenorphine is a partial opioid agonist that can reduce withdrawal and craving while having a ceiling effect on some respiratory effects. It is available in several formulations and is sometimes combined with naloxone to discourage injection. It remains an opioid medicine and can cause sedation, especially with other depressants.
Starting buprenorphine requires attention to the timing of last opioid use and withdrawal. Fentanyl exposure can make initiation more complex. People should follow a clinician’s plan rather than a universal online schedule.
Naltrexone
Naltrexone blocks opioid receptors and does not produce opioid effects. It may be used after a sufficient opioid-free period. Starting too soon can precipitate severe withdrawal, so the interval and assessment are important. It does not relieve early withdrawal or craving during that required period.
Adherence, access and patient preference affect whether naltrexone is a practical option. The extended-release formulation can reduce the need for daily dosing where available.
How treatment is selected
Choice depends on current opioid use, previous response, overdose history, pregnancy, pain, physical health, other medicines, access and personal preference. A person who did not do well with one medication may still benefit from another or from a different dose and support structure.
The decision should be collaborative. Services should explain benefits, risks, expected follow-up and what happens if doses are missed. A programme philosophy should not override informed clinical care.
Medication and pregnancy
Methadone and buprenorphine are established treatment options during pregnancy within coordinated obstetric and addiction care. Abrupt withdrawal and relapse can create serious risks. The exact medicine and plan should be selected by specialists who can coordinate prenatal, delivery and neonatal care.
Pregnant patients deserve confidential, non-stigmatising treatment. Fear of child-protection or legal consequences should not delay medical care.
Medication and pain
People taking methadone or buprenorphine can still need treatment for acute or chronic pain. Surgical, dental and emergency clinicians should know the medication and coordinate with the prescriber. Stopping treatment abruptly can worsen both pain and opioid risk.
A multimodal pain plan may include non-opioid medicines, rehabilitation, psychological strategies and, when necessary, additional analgesia under supervision.
Benzodiazepines and other sedatives
Combining opioid medicines with benzodiazepines, alcohol or other central nervous system depressants increases breathing risk. Patients should disclose all use and seek urgent help for unusual sedation or breathing difficulty. Prescribers may increase monitoring, coordinate a gradual sedative reduction or adjust treatment.
Medication for opioid use disorder should not be withheld automatically because a person uses benzodiazepines. Untreated opioid use also carries a high risk of death. The plan should manage both risks carefully.
Monitoring and dose review
Monitoring considers withdrawal, craving, sedation, illicit use, side effects, function and adherence. A dose that is too low may leave persistent withdrawal and drive continued use, while an excessive dose may cause sedation. Changes require clinical review.
Drug testing can support treatment but should be used transparently and interpreted with limitations. Unexpected results are a reason for conversation and safety planning, not automatic discharge.
Psychological and practical support
Medication addresses opioid physiology, while counselling, peer support and practical services can address trauma, routines, relationships, housing and employment. These supports should be available without making medication conditional on perfect attendance or abstinence.
Some people need little formal therapy and still benefit from medication. Others need intensive integrated care. Treatment should be tailored rather than forcing every patient through the same programme.
What happens after a lapse
A return to opioid use is an overdose risk because supply and tolerance may have changed. Review dose, missed medication, stress, pain and access. Provide naloxone and increase support quickly.
Removing medication after a lapse can make the situation more dangerous. Retention and rapid re-engagement are important treatment goals.
Stopping medication
There is no medically required deadline. A person considering a reduction should be stable, informed about overdose risk and supported by the prescriber. A slow, individual plan may reduce withdrawal, but relapse can still occur after medication ends.
Naloxone and rapid access back to treatment are essential. The ability to restart should be treated as part of safety, not as failure.
Residential and luxury rehab policies
A residential or luxury rehab should disclose whether it initiates and continues methadone or buprenorphine, who prescribes and how medication will continue after discharge or international travel. Requiring cessation for admission can create avoidable risk.
Privacy and accommodation are secondary to medication continuity, qualified medical care and emergency response. Verify the exact site’s policy before paying a deposit or travelling.
How medication supports recovery
Recovery can include stable medication, no illicit opioid use, improved health, safer relationships and meaningful daily life. A person does not need to stop an effective medicine to prove recovery.
Yes. Treatment should be matched to the substance or behaviour, severity, withdrawal and overdose risk, physical and mental health, previous response, goals, and available support. More than one episode of care may be needed.
Does withdrawal mean someone has an addiction?
Not necessarily. Withdrawal can indicate physical dependence, including during appropriate prescribed treatment. Addiction additionally involves impaired control, prioritisation, and continued use despite harm. A clinician can distinguish these patterns.
What is the safest first step?
Arrange a confidential assessment with a qualified addiction or medical service. Use emergency services immediately for overdose, seizure, breathing difficulty, severe confusion, dangerous psychosis, or immediate suicide risk.
Sources and clinical guidance
Sources are selected for clinical authority and public accessibility. Publication does not imply endorsement of any treatment provider.
Yes. Treatment should be matched to the substance or behaviour, severity, withdrawal and overdose risk, physical and mental health, previous response, goals, and available support.
Does withdrawal always mean someone has an addiction?
No. Withdrawal can indicate physical dependence, including during appropriate prescribed treatment. Addiction additionally involves impaired control, prioritisation, and continued use despite harm.
What is the safest first step?
Arrange a confidential assessment with a qualified addiction or medical service. Use emergency services immediately for overdose, seizure, breathing difficulty, severe confusion, dangerous psychosis, or immediate suicide risk.
Prepared by the AddictionInfo Editorial Team and last evidence-checked on September 4, 2026. We distinguish education from medical advice, link material claims to primary or authoritative sources, and correct substantive errors transparently. Read our editorial standards.
Opioid tolerance can fall quickly during detoxification, hospitalisation, incarceration, residential treatment, or a period of non-use. Returning to a previously tolerated amount…
Opioid withdrawal often causes aches, sweating, yawning, nausea, vomiting, diarrhoea, anxiety, insomnia, and intense craving. It is usually not directly fatal in…